13th Winter Conference

Medicinal and Bioorganic Chemistry

Sheraton Steamboat Springs Resort 22 - 26 January 2017

Sunday 22nd January 2017

SUNDAY PM - MBCF Drughunter Award
Chairman: Dr Matthew M. Hayward, Pfizer, USA

Dr Mark Flanagan, Pfizer, USA
Discovery of Xeljanz

Drug Discovery in Autoimmunity
Chairmen: Dr Timothy Richardson and Dr Daniel Dairaghi, Eli Lilly, USA

Dr Penglie Zhang, ChemoCentryx, USA
CCR1 Antagonist

Dr James Crawford, Genentech, USA
Discovery of GDC-0853: A Highly Potent, Selective, and Non-Covalent Btk Inhibitor

Dr Linghang Zhuang,
Vitae Pharmaceuticals, Inc., an Allergan affiliate, USA
Discovery of VTP-43742, A RORgt Inverse Agonist for the Treatment of Psoriasis

Dr Les Miranda,
Amgen, USA
Peptide Antagonists of Kv1.3 

Monday 23rd January 2017

MONDAY AM - Liquid Biopsy Platforms as Biomarkers in Oncology Clinical Trials and as Companion Diagnostics
Chairman: Dr Daniel Flynn, Deciphera Pharmaceuticals, USA

Dr Bryan Smith, Deciphera Pharmaceuticals, USA
Detecting Circulating Tumor Cells in Clinical Trials - Making Circulating Tumor Cells Glow using a Telomerase-based Assay

Mr Daniel Simon, Guardant Health, Inc, USA
Accelerating Clinical Trials using NGS Liquid Biopsy

Dr Robert Shoemaker, Ignyta, Inc, USA 
Using ctDNA Biomarkers in Ignyta’s Clinical Trials: Detecting Activating Alterations, Monitoring Drug Efficacy, and Detecting Resistance Mechanisms

Dr Johan Skog, Exosome Diagnostics, USA
Bringing Exosome Liquid Biopsy Technology into the Realm of Routine Clinical Use

Dr Sid Scudder, Roche Molecular Systems, USA
Cell Free DNA Analysis of NSCLC Patients as a Paradigm for Clinical use of Liquid Biopsies

MONDAY PM - Advances in PET Imaging
Professor Michael VanNieuwenhze, Indiana University, USA and Dr Shane Krska, Merck, USA

Dr Neil Vasdev, Harvard Medical School, USA
Cutting-Edge PET Radiochemistry Methodologies Applied to Drug Development

Dr Shane Krska, Merck, USA
Enabling Late Stage Fluorination Methods for the Discovery and Radiosynthesis of PET Imaging Agents

Dr Hartmuth Kolb, Johnson & Johnson, USA
Development of PET Imaging Tracers for Neuroscience Applications

Professor David Perrin, University of British Columbia, USA
Empowering Preclinical PET Imaging: Facile and User-Friendly 18F-labeling of Complex Molecules

Tuesday 24th January 2017

TUESDAY AM - Advances in Modern Synthetic Methods
Chairman: Professor Victor Snieckus, Queens University, Canada

Dr Gerald Tanoury, Vertex, USA
Converting a Medicinal Chemistry Synthesis into a Manufacturing Process

Dr Antonia Stepan, Pfizer, USA
C-H Functionalization Methods as Cutting-Edge Synthesis Tools for Medicinal Chemists

Dr Carl Busacca, Boehringer Ingelheim, USA
Hydrophosphinations of Strained Rings

Dr Neil Garg, University of California, Los Angeles, USA
Recent Forays in Methods Development and Complex Molecule Synthesis

TUESDAY PM - Post-Phenotypic Screen Target Identification
Chairmen: Dr Philippe Nantermet and Dr Scott Wolkenberg, Merck, USA

Dr Monica Schenone, Broad Inst, USA
Target ID Successes and Lessons

Dr Donovan Chin, Novartis, USA
Computational Approaches to Target ID Using Large Scale Protein-Ligand Modeling

Dr Andrea Zuhl
, AstraZeneca, USA
A Chemoproteomic Approach to Identify Drivers of BACE1 Inhibitor Ocular Toxicity

Dr Susanne Swalley, Novartis, USA
The Splice is Right: Phenotypic Drug Discovery and Target ID for Spinal Muscular Atrophy 

Wednesday 25th January 2017

WEDNESDAY AM - Biophysical Tools in Drug Discovery and Chemical Biology
Chairman: Dr Lyn Jones, Pfizer, USA

Professor Ralph Mazitschek, Harvard University, USA
Light-controlled Modulation of Gene Expression by Chemical Optoepigenetic Probes

Dr Gerard Drewes, Cellzome / GlaxoSmithKline, USA
Tracking Drug Action by Chemical Proteomics

Dr Matthew Clark, X-Chem, USA
Principles and Applications of DNA-Encoded Library Technologies

Dr Lyn Jones, Pfizer, USA
Biophysical and Chemical Methods to Interrogate Drug-Target Engagement

WEDNESDAY PM - General Session on Medicinal and Synthetic Chemistry Chairmen: Professor Anthony Barrett, Imperial College, UK and Dr Matthew M. Hayward, Pfizer, USA

General Session Abstract Submission is now Closed. You can still submit a Poster Abstract. Please send your contribution to This email address is being protected from spambots. You need JavaScript enabled to view it. - deadline January 14th 2017. Confirmed speakers are as follows:

Dr Petr Vachal, Merck
Merck Drug Discovery Enabled

Dr Giles Brown, Heptares
Structure-based drug design with G protein-coupled receptors: The discovery of Highly Selective M1 Agonists

Dr Ryan White, Amgen
Accounting for Lysosomotropism as a Strategy for Prioritizing Selective Inhibitors of BACE

Dr Klemens Hoegenauer, Novartis
The Discovery of a New Generation of Potent and Selective PI3Kδ Inhibitors

Dr Louis Chupak, Bristol Myers Squibb
Chemically Non-Reactive Glycine Sulfonamide Inhibitors of Diacylglycerol Lipase

Dr Sarah Trice, Sigma Aldrich
Modern Chemistry: Tools to Enable the Practicing Chemist

Dr Leonard Winneroski, Eli Lilly
Preparation and Biological Evaluation of trans-Cyclopropyl-linked BACE1 Inhibitors

Thursday 26th January 2017

THURSDAY AM - Viral Diseases Eradication
Chairman: Dr Philippe Nantermet, Merck, USA

Dr John McCauley, Merck, USA
Invention of Grazoprevir, a Hepatitis C NS3 Protease Inhibitor

Dr Will Watkins, Gilead, USA
Inhibition of the HCV Polymerase NS5B as a Means Towards Curative Therapy

Dr Nick Meanwell, Bristol Myers Squib, USA
The Discovery of HCV NS5A Replication Complex Inhibitors

Dr Mike Sofia, Arbutus Biopharma, Inc., USA
Hepatitis B: Is There a Path to a Cure?

Dr Daria Hazuda, Merck, USA
What will it take to Eradicate HIV: A Drug Discovery Perspective

THURS PM - Key Note Speaker

Dr Steven D. Young, VP Basic Research (retired) Merck & Co.; Scientific Consultant and Acting Head of Chemistry, BeiGene LTD

'Tackling a Pandemic Disease: A History of HIV Drug Discovery at Merck'

PLUS Poster Session - This email address is being protected from spambots. You need JavaScript enabled to view it.for approval - deadline January 14th 2017.

  • Payment is required at the time of registration.
    Only registrations accompanied with payment will be accepted. Please register in advance.
    Fees include course materials, welcome reception, keynote address and banquet and reception at poster session.

    A full refund of registration fees, less a $30 administrative fee, will be available if requested in writing and received by December 24th 2016.
    No refunds will be made after that date. A $30 fee also will be charged for returned checks.
    (Please note that if you fail to cancel by the deadline and do not attend, you are still responsible for payment.)

    MBCF reserves the right to cancel the 13th Winter Conference on Medicinal & Bioorganic Chemistry and return all fees in the event of insufficient registration. The liability of the MBCF and its partners is limited to the registration fee. The MBCF will not be responsible for any losses incurred by registrants, including but not limited to airplane cancellation charges or hotel deposits.

  • Early Bird Fee (before 1st December)
    Conference Fee (after 1st December)
    Student / Post Doc Fee (not for Faculty members)
    Exhibitor Fee (includes a 6ft table and one registrant)


    Registration is now OPEN. You will be re-directed to our partners at Scientific Update to complete this process. Please click on the button below:


Media Sponsors

  • CSBJ-Logo-small
  • ChemMedChem_logo_CPSE_200
  • TechNet_logo_web_dark
  • american_element
  • jmclogo-jpg
  • mcllogo-jpg
  • thieme
  • wiley_imp_clpr_k